BURT A ADELMAN
CIK 1226283 · CMO & EVP, R&D · last filed 2025-07-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.76M
Companies
4
Total Filings
35
Lifetime Open-Market Net
-$21.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Verve Therapeutics, Inc. (VERV) Delisted | Director | 0 | $11.13 | $0 | $354.4K | 8 | 2025-07-28 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 5 | 2020-06-12 |
| DYAX CORP (DYAX) Delisted | CMO & EVP, R&D | 0 | — | — | -$1.73M | 11 | 2016-01-22 |
| BIIB | EVP, Portfolio Strategy | 43,778 | $200.05 | $8.76M | -$20.17M | 11 | 2007-10-17 |
Recent Filings · Page 4 of 4
35 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-03-22 | BIIB | Sell (S) | −6,634 | -$295.1K | EDGAR |
| 2007-03-16 | BIIB | Mixed | +6,634 | -$201.6K | EDGAR |
| 2007-02-15 | BIIB | Sell (S) | −11,871 | -$584.2K | EDGAR |
| 2007-02-14 | BIIB | Grant (A) | +12,500 | $0 | EDGAR |
| 2007-02-08 | BIIB | Mixed | −129 | -$273.9K | EDGAR |
Showing 31–35 of 35
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.